Saniona Past Earnings Performance
Past criteria checks 0/6
Saniona's earnings have been declining at an average annual rate of -9.7%, while the Biotechs industry saw earnings growing at 7.7% annually. Revenues have been growing at an average rate of 3.7% per year.
Key information
-9.7%
Earnings growth rate
2.2%
EPS growth rate
| Biotechs Industry Growth | -14.6% |
| Revenue growth rate | 3.7% |
| Return on equity | -1,179.8% |
| Net Margin | -328.8% |
| Next Earnings Update | 28 Nov 2024 |
Recent past performance updates
Recent updates
Revenue & Expenses Breakdown
How Saniona makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 30 Jun 24 | 25 | -82 | 76 | 0 |
| 31 Mar 24 | 21 | -83 | 77 | 0 |
| 31 Dec 23 | 17 | -96 | 81 | 0 |
| 30 Sep 23 | 15 | -108 | 52 | 0 |
| 30 Jun 23 | 12 | -33 | 44 | 0 |
| 31 Mar 23 | 11 | -100 | 113 | 0 |
| 31 Dec 22 | 15 | -212 | 229 | 0 |
| 30 Sep 22 | 15 | -334 | 330 | 0 |
| 30 Jun 22 | 15 | -445 | 439 | 0 |
| 31 Mar 22 | 14 | -461 | 450 | 0 |
| 31 Dec 21 | 10 | -411 | 409 | 0 |
| 30 Sep 21 | 9 | -326 | 352 | 0 |
| 30 Jun 21 | 9 | -280 | 300 | 0 |
| 31 Mar 21 | 9 | -200 | 225 | 0 |
| 31 Dec 20 | 8 | -73 | 160 | 0 |
| 30 Sep 20 | 11 | -25 | 113 | 0 |
| 30 Jun 20 | 9 | -5 | 102 | 0 |
| 31 Mar 20 | 8 | -1 | 95 | 0 |
| 31 Dec 19 | 7 | -69 | 95 | 0 |
| 30 Sep 19 | 5 | -96 | 110 | 0 |
| 30 Jun 19 | 49 | -53 | 108 | 0 |
| 31 Mar 19 | 52 | -52 | 115 | 0 |
| 31 Dec 18 | 55 | -41 | 104 | 0 |
| 30 Sep 18 | 57 | -32 | 89 | 0 |
| 30 Jun 18 | 17 | -61 | 85 | 0 |
| 31 Mar 18 | 17 | -56 | 79 | 0 |
| 31 Dec 17 | 21 | -49 | 74 | 0 |
| 30 Sep 17 | 21 | -47 | 74 | 0 |
| 30 Jun 17 | 68 | -6 | 71 | 0 |
| 31 Mar 17 | 67 | -2 | 67 | 0 |
| 31 Dec 16 | 75 | 2 | 69 | 0 |
| 30 Sep 16 | 71 | 10 | 56 | 0 |
| 30 Jun 16 | 23 | -25 | 52 | 0 |
| 31 Mar 16 | 25 | -21 | 46 | 0 |
| 31 Dec 15 | 14 | -23 | 39 | 0 |
| 30 Sep 15 | 16 | -23 | 41 | 0 |
| 30 Jun 15 | 19 | -16 | 36 | 0 |
| 31 Mar 15 | 23 | -10 | 33 | 0 |
| 31 Dec 14 | 22 | -6 | 27 | 0 |
| 31 Dec 13 | 13 | -1 | 14 | 0 |
Quality Earnings: 30S is currently unprofitable.
Growing Profit Margin: 30S is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 30S is unprofitable, and losses have increased over the past 5 years at a rate of 9.7% per year.
Accelerating Growth: Unable to compare 30S's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 30S is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-18.2%).
Return on Equity
High ROE: 30S has a negative Return on Equity (-1179.78%), as it is currently unprofitable.